In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Molecular Biosystems Inc.

Latest From Molecular Biosystems Inc.

Amersham's Push for High-Value Diagnostics

Amersham Health is applying Big Pharma marketing and R&D strategies to the traditionally stodgy, highly price-sensitive field of diagnostic imaging contrast agents. It has been far more aggressive than competitors in working to make innovation the basis of competition. But some analysts question whether the company can maintain near-to-mid-term growth as it awaits results of its risky, long-term effort in molecular imaging.

BioPharmaceutical Medical Device

Point Biomedical: Planning for Uncertainty

Point Biomedical is developing a third-generation ultrasound contrast agent before second-generation agents have been successfully adopted. But as a small company, it must make choices about what it can realistically handle and what it can't--thus it is purusing a second business in acoustic drug delivery, but passing on urological and surgical applications of its biomaterials technology.

BioPharmaceutical Medical Device

Point Biomedical Corp.

Biomaterials. Point Biomedical's expertise is in biodegradable polymers, tailored for {in vivo} residence time, biological reactivity and tissue integration properties. The company is developing ultrasound contrast agents, a urological drug delivery implant, and surgical adhesives with improved handling and tissue integration properties.

BioPharmaceutical Medical Device

Contrast Media Manufacturers Lock Up Distribution Channels

Thanks to the continued conversion of customers to non-ionic contrast media, the market for contrast agents exploded to phenomenal heights in the last decade. But with growth slowing, manufacturers are looking to cement their grip on distribution channels through big acquisitions.

See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents